Guangzhou Henovcom Bioscience Co. Ltd. has identified new imidazole TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, hepatic fibrosis, inflammation, osteoporosis, Alzheimer's disease, idiopathic pulmonary fibrosis, diabetic nephropathy and renal disorders, among other disorders.